534 was designed to be a pan BCR-ABL inhibitor rather than T315I specific. However, the management is looking for third-line now and other solid tumor indications. Maybe when the drug is approved they will run a head to head with Tasigna and Sprycel.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.